Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. (PFE), headquartered at The Spiral in Manhattan, New York City, is a leading American multinational pharmaceutical and biotechnology corporation established in 1849 by Charles Pfizer and his cousin Charles F. Erhart. Pfizer stands as one of the world's largest pharmaceutical companies, with annual sales nearing $50 billion, excluding COVID-19 product sales.
Pfizer's core business revolves around the development, manufacturing, and global distribution of prescription drugs and vaccines. Its top-selling products include the pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. These products contribute significantly to Pfizer's global sales, with nearly 50% of revenues coming from international markets, and emerging markets playing a crucial role.
In recent news, Pfizer continues to make strides in cancer treatment through its collaboration with Astellas and Merck. A key focus has been on the promising cancer therapeutic combinations involving PADCEV™ (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab), targeting metastatic urothelial cancer. This collaboration underscores Pfizer's commitment to advancing cancer treatments and improving patient outcomes worldwide.
Financially, Pfizer remains robust, continually investing in research and development to innovate and expand its portfolio of treatments addressing unmet medical needs. Strategic partnerships and collaborations further enhance its position in the market, ensuring a steady pipeline of new and effective therapeutic solutions.
With a rich history and a steadfast commitment to healthcare innovation, Pfizer Inc. continues to be a significant player in the pharmaceutical industry, dedicated to improving global health through advanced medical research and groundbreaking therapies.
Pfizer (NYSE: PFE) announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® in combination with XTANDI® for metastatic castration-resistant prostate cancer (mCRPC). The study showed significant improvement in overall survival across two patient cohorts:
In unselected patients (Cohort 1), the combination therapy achieved a median overall survival of 45.8 months versus 37.0 months with XTANDI and placebo, representing a 20% reduction in death risk and nearly 9-month survival gain. In HRR-mutated patients (Cohort 2), median overall survival was 45.1 months versus 31.1 months with XTANDI and placebo, showing a 38% reduction in death risk and 14-month survival improvement.
The safety profile aligned with known characteristics of both medicines, with common adverse events including anemia, neutropenia, and fatigue. The data has been shared with FDA, EMA, and other global health authorities for potential label updates.
Pfizer (NYSE: PFE) has received FDA approval for ADCETRIS® combination therapy for treating relapsed/refractory large B-cell lymphoma (LBCL). The approval is based on the Phase 3 ECHELON-3 trial results, which showed the ADCETRIS regimen reduced death risk by 37% compared to standard treatment.
The therapy is specifically approved for adult patients with LBCL who have undergone two or more lines of systemic therapy and are not eligible for stem cell transplantation or CAR-T therapy. This marks ADCETRIS's eighth FDA-approved indication.
The ECHELON-3 study demonstrated significant improvement in overall survival, with benefits consistent across CD30 expression levels. More than 3,500 patients annually in the U.S. experience treatment failure after two prior therapy lines for this aggressive form of non-Hodgkin lymphoma.
Pfizer (PFE) and Astellas announced extended follow-up results from their Phase 3 EV-302 trial, evaluating PADCEV® plus KEYTRUDA® in first-line treatment of locally advanced or metastatic urothelial cancer. After 29.1 months of median follow-up, the combination therapy showed significant improvements over chemotherapy:
- Reduced death risk by 49% (HR = 0.51)
- Median overall survival: 33.8 months vs 15.9 months for chemotherapy
- Reduced disease progression risk by 52% (HR = 0.48)
- Median progression-free survival: 12.5 months vs 6.3 months for chemotherapy
The confirmed objective response rate was 67.5% for the combination vs 44.2% for chemotherapy, with complete response rates of 30.4% vs 14.5% respectively. The safety profile remained consistent with previous findings, with no new concerns identified.
Pfizer (PFE) reported strong financial results for full-year 2024, with revenues of $63.6 billion, showing 7% year-over-year operational growth. Excluding Paxlovid and Comirnaty contributions, revenues grew 12% operationally.
Fourth-quarter 2024 revenues reached $17.8 billion, with 21% operational growth excluding COVID products. The company reported full-year 2024 adjusted diluted EPS of $3.11 and fourth-quarter adjusted diluted EPS of $0.63.
Pfizer reaffirmed its 2025 financial guidance, projecting revenues between $61.0 to $64.0 billion and adjusted diluted EPS of $2.80 to $3.00. The company is on track to deliver overall net cost savings of approximately $4.5 billion by end of 2025 from its ongoing cost realignment program.
Pfizer (PFE) announced positive topline results from the Phase 3 BREAKWATER study of BRAFTOVI® combination therapy for metastatic colorectal cancer (mCRC) with BRAF V600E mutation. The study demonstrated statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS) compared to standard chemotherapy.
The BRAFTOVI combination regimen, which includes cetuximab and mFOLFOX6, received accelerated FDA approval in December 2024 for treatment-naïve patients based on improved objective response rate (ORR). The safety profile remained consistent with known profiles of each agent, with no new safety signals identified.
These results will be shared with the FDA to support potential conversion to full approval and with other global regulatory authorities for additional license applications.
Pfizer (PFE) will present significant advancements in genitourinary cancer treatments at the ASCO GU Cancers Symposium in San Francisco. The company will showcase more than 20 abstracts, including five oral presentations, focusing on prostate and bladder cancers.
Key highlights include detailed overall survival results from the Phase 3 TALAPRO-2 trial of TALZENNA® with XTANDI® in metastatic castration-resistant prostate cancer, which demonstrated statistically significant improvements. Updated analysis from the Phase 3 EV-302 trial shows sustained overall survival benefits of PADCEV® combined with pembrolizumab in advanced urothelial cancer.
The company will also present the first randomized progression-free survival data for mevrometostat with XTANDI in mCRPC. Pfizer's genitourinary portfolio includes seven approved medicines across bladder, prostate, and kidney cancers, with TALZENNA-XTANDI combination already approved in over 35 countries globally.
Pfizer (PFE) announced positive Phase 3 BREAKWATER trial results for BRAFTOVI® combination therapy in treating BRAF V600E-mutant metastatic colorectal cancer (mCRC). The trial showed a significantly higher objective response rate of 60.9% compared to 40% with standard chemotherapy.
Key findings include a median duration of response of 13.9 months for the BRAFTOVI combination versus 11.1 months for chemotherapy. Additionally, 22.4% of BRAFTOVI-treated patients maintained response for 12+ months, compared to 11.4% in the chemotherapy group.
While overall survival data is not yet mature, early trends favor the BRAFTOVI combination. The safety profile aligned with known profiles of individual components, with serious treatment-emergent adverse events occurring in 37.7% of BRAFTOVI combination patients versus 34.6% in the chemotherapy group. The FDA granted accelerated approval for this treatment in December 2024.
Pfizer (PFE) announced positive topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody, combined with BCG therapy for high-risk non-muscle invasive bladder cancer (NMIBC). The study met its primary endpoint, showing significant improvement in event-free survival compared to BCG alone.
The treatment could potentially be the first PD-1 inhibitor approved in combination with BCG for this indication, representing the first major advancement in BCG-naïve, high-risk NMIBC treatment in over 30 years. Approximately 100,000 people globally are diagnosed with high-risk NMIBC annually, with 40-50% experiencing recurrent disease.
The safety profile of sasanlimab with BCG was consistent with known profiles of both treatments. Pfizer plans to submit the results to regulatory authorities and present them at upcoming medical conferences.
Pfizer Inc. (NYSE: PFE) has announced a public webcast featuring a discussion with Albert Bourla, Chairman and CEO, at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 9:45 a.m. PST.
The webcast will be accessible through www.pfizer.com/investors, with registration details available immediately. A transcript and replay will be posted within 24 hours and remain accessible for at least 90 days.
Pfizer, with a 175-year legacy, focuses on developing breakthrough therapies and vaccines that improve lives globally. The company emphasizes quality, safety, and value in healthcare product development, working across developed and emerging markets to advance wellness and treatments for major diseases. They collaborate with healthcare providers, governments, and communities to expand access to affordable healthcare worldwide.
Stuart Therapeutics has appointed Tracy Valorie and Jason Werner to its Board of Directors, expanding it to five members. They replace Robert O. Baratta, MD, who passed away in Q3, and Diane Black, RN, who resigned. Valorie, owner of TMV Associates , brings 30 years of pharmaceutical and biotech experience, including senior roles at Bausch + Lomb and Pfizer. Werner serves as Executive Chairman of Sightstream Biotherapeutics and has extensive experience in ophthalmology, including co-founding Eyevance Pharmaceuticals. Both appointments strengthen Stuart's leadership as it advances in ophthalmology therapeutics development and commercialization.
FAQ
What is the current stock price of Pfizer (PFE)?
What is the market cap of Pfizer (PFE)?
What is Pfizer Inc. known for?
Where is Pfizer's headquarters located?
How much does Pfizer make annually?
What are some of Pfizer's top-selling products?
What is the significance of Pfizer's international sales?
What recent collaborations has Pfizer been involved in?
When was Pfizer founded?
What is Pfizer's approach to innovation?
How does Pfizer contribute to cancer treatment?
What role do strategic partnerships play for Pfizer?
